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INTRODUCTION
In 1964, James (1) observed a high incidence of
gastric metaplasia (GM) in patients with duodenal
ulcer, and suggested its role in the defense against
high gastric acidity. Since the discovery of Helicobacter
pylori (H. pylori) in 1983 (2), a close association
between this bacterium and duodenal ulcer has
been suggested. However, no consistent results or
conclusions have been obtained concerning changes
in GM after H. pylori eradication.
We classified the morphology of GM into 3 types
according to the amount of mucus in metaplastic
cells and evaluated the long-term course of GM
after H. pylori eradication.
METHODS
Patients
The subjects were 59 H. pylori -positive patients with
active duodenal ulcers who were undergoing endo-
scopic examination. Patients who had received anti-
biotics, acid suppression treatment, or corticosteroids
in the previous month or who were receiving nonsteroidal
anti-inflammatory drugs were excluded. Patients in
whom gastric surgery was performed, or endoscop-
ic biopsy was contraindicated were also excluded.
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In 40 patients (25 males and 15 females ; median
age, 51 years ; age range, 33-72 years), H. pylori
could be eradicated by triple drug therapy with
lansoplazole, amoxicillin, and metronidazole (eradi-
cation group). In the other 19 patients (13 males and
6 females ; median age, 48 years ; age range, 26-70
years), H. pylori were not eradicated (non-eradication
group).
Clinical procedures
The eradication group received 1.5 g/day of
amoxicillin and 500 mg/day of metronidazole for 1
week, and 30 mg/day of lansoplazole for 6 weeks
after initial endoscopic examination, followed by
consecutive administration of an H2-receptor antago-
nist at the standard dose for 4 weeks.
The non-eradication group received 30 mg/day
of lansoplazole for 6 weeks after initial endoscopy
and, in addition, received the same regimen of an
H2-receptor antagonist as the successful eradication
group.
At the initial endoscopy, two paired biopsies were
obtained from the greater curvature of the gastric
antrum as well as of the gastric corpus in all patients
in both groups. Of the two paired biopsies, one was
used for the rapid urease test, and the other was
placed in 10% buffered formalin for histological ex-
amination to confirm H. pylori infection.
Two duodenal biopsies were performed from the
ulcer margin at the same time and also placed in
10% buffered formalin and processed for the histo-
logical examination of GM.
All patients in both groups underwent endosco-
py again after treatment for 10 weeks. Gastric biopsies
were repeated, being obtained from a topographi-
cal site similar to that in the initial endoscopy. Two
duodenal biopsy specimens were obtained from the
center of the scar.
The 40 patients in the eradication group were
followed up for 2.0-7.1 years (mean, 3.6 years) after
confirmation of eradication to evaluate the course
of duodenal ulcer and examine for H. pylori . Endos-
copy was performed once-7 times (mean, 2.9 times)
after the confirmation of H. pylori eradication. At
each endoscopy, biopsy specimens were obtained
from the stomach and the center of the duodenal
ulcer scar by the above-described method. In pa-
tients with recurrence, biopsy specimens were ob-
tained from the ulcer margin in the same way as in
the initial endoscopy.
Of patients who could be followed up in the
non-eradication group, 6 did not show recurrence.
In the 6 patients, biopsy specimens were obtained
from the greater curvature of the gastric antrum
and corpus and the center of the duodenal ulcer
scar, and H. pylori and GM were examined.
The eradication of H. pylori was confirmed by a
negative biopsy urease test and negative results of
histological examination.
Informed consent about the eradication of H. pylori
and endoscopic biopsy was obtained from all pa-
tients who entered this study.
Histological methods
Duodenal and gastric sections were routinely pro-
cessed, cut at 3 µm, and stained with hematoxylin-eosin,
alcian blue periodic acid Schiff, and Giemsa stain.
Duodenal sections stained with hematoxylin-eosin
and alcian blue periodic acid Schiff were used to
identify and assess the extent and type of GM. Giemsa
stain was used to identify the presence of H. pylori
in areas of GM. Hematoxylin-eosin staining of gas-
tric biopsy specimens was performed for histologi-
cal examination for gastritis, and Giemsa stain was
used for the detection of H. pylori .
The extent of GM was classified according to our
previously reported method : (3-5) grade 0, absence
of GM ; grade 1, GM involving a few villi ; grade 2,
GM involving several villi ; and grade 3, GM involv-
ing almost all villi.
GM was classified into 3 types according to the
amount of mucus in the metaplastic cells : complete,
intermediate, and incomplete (5). The complete type
of GM was characterized by tall mucin-abundant
cells (Fig. 1). The incomplete type of GM was dark
with cuboidal cells poor in mucin (Fig. 2). The inter-
mediate type was between the two types.
When the grade differed between the two speci-
mens from the same subject, the higher grade was
Fig. 1. Complete-type gastric metaplasia. Tall columnar metaplastic
cells were abundant in mucin (hematoxylin and eosin, ×75).
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regarded as the grade for that subject.
Statistics
Statistical analysis was performed using Wilcoxon’s
signed rank test. P values < 0.05 were considered
significant.
RESULTS
Changes in GM in the eradication group
Table 1 shows changes in the type of GM before
and after 10 weeks of treatment in the 40 patients
with duodenal ulcer in the successful eradication
group. Before eradication (active stage of duodenal
ulcer), the incomplete type was observed in 35 of
the 40 patients and the intermediate type in the
other 5. After H. pylori eradication (scarring stage),
the complete type was observed in 39 patients and
the intermediate type in the other. Thus, the incom-
plete type of GM was frequently observed before
eradication, but the complete type was primarily
observed after eradication (p<0.0001).
Before eradication, the extent of GM was graded
as 0 in none of the 40 patients, 1 in 13, 2 in 19, and
3 in 8. After eradication, grade 0 was observed in
none of the 40 patients, grade 1 in none, grade 2 in
5, and grade 3 in the other 35 (Table 2). The ex-
tent of GM after eradication was greater than that
before eradication (p<0.0001).
Long-term course of GM in the successful eradica-
tion group
Fig. 3 shows the course of GM after H. pylori
eradication in the 40 patients who were followed
up for 2 years or more after eradication. In most
patients showing a change to the complete type after
eradication, this state was maintained for a long
period. However, in 5 patients, the complete type
changed to the intermediate type during the follow-up
period. In 3 patients who became H. pylori -positive
again, GM changed to the incomplete type, and the
extent of GM also decreased. Of the other 37 pa-
tients who were consistently H. pylori -negative, 15
showed a decrease in the extent of GM 1.5 - 4.5
years after eradication. However, in some patients,
grade 3 GM persisted for 3 to 7 years.
Changes in GM in the non-eradication group
Table 3 shows GM types before (active stage of
duodenal ulcer) and after (scarring stage) treat-
ment in the 19 patients with duodenal ulcer in the
non-eradication group. Before treatment, the com-
plete type was observed in none of the 19 patients,
intermediate type in 3, and the incomplete type in
16. After treatment for 10 weeks, the complete type
was observed in 6 patients, intermediate type in 6,
Fig. 2. Incomplete-type gastric metaplasia. Metaplastic cells were
smaller and contained a lower amount of mucin (hematoxylin
and eosin, ×75).
Table 1. Type of gastric metaplasia before and after eradication of H. pylori (successful eradication group)
Complete Intermediate Incomplete
Before eradication (n=40)
After eradication (n=40)
0
39
5
1
35
0
P<0.0001
Table 2. Extent of gastric metaplasia before and after eradication of H. pylori (successful eradication group)
Grade 0 Grade 1 Grade 2 Grade 3
Before eradication (n=40)
After eradication (n=40)
0
0
13
0
19
5
8
35
P<0.0001
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and incomplete type in 7. The incomplete type was
frequently observed in the active stage while the
complete type increased, and the incomplete type
decreased in the scarring stage (p=0.0024).
The extent of GM before treatment was graded
as 1 in 7 patients and 2 in 12, and that after treat-
ment was graded as 2 in 4 patients and 3 in 15
(Table 4). Thus, the extent of GM in the scarring
stage was greater than that in the active stage (p<
0.0001).
Course of GM in patients without ulcer recurrence
in the non-eradication group
Fig. 4 shows the course of GM in 6 patients with-
out ulcer recurrence during the follow-up period
in the non-eradication group. The follow-up period
Fig. 3. Changes in gastric metaplasia
after successful eradication.
Table 3. Type of gastric metaplasia in the active stage and scarring stage (non-eradication group)
Complete Intermediate Incomplete
Active stage (n=19)
Scarring stage (n=19)
0
6
3
6
16
7
P<0.0024
Table 4. Extent of gastric metaplasia in the active stage and scarring stage (non-eradication group)
Grade 0 Grade 1 Grade 2 Grade 3
Active stage (n=19)
Scarring stage (n=19)
0
0
7
0
12
4
0
15
P<0.0001
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ranged from 7 to 23.5 months (mean, 14.3 months).
Before treatment (active stage), all the 6 patients
showed the incomplete type. After 10 weeks of
treatment (scarring stage), the complete type was
observed in 2 patients, intermediate type in 3, and
the incomplete type in 1. The extent of GM before
treatment was graded as 1 in 2 patients and 2 in 4,
but that after treatment was graded as 3 in all the 6
patients. Follow up examination showed a change
to the incomplete type again and a decrease in the
extent of GM in most patients despite the mainte-
nance of the ulcer scarring stage.
Thus, the non-eradication group showed a lower
incidence of complete type GM in the scarring stage
than the successful eradication group. In addition,
the extent of GM, which increased in the scarring
stage, decreased after a short period.
DISCUSSION
GM has been considered to be a protective re-
sponse to exposure to high acidity in the duodenal
bulb (1, 6-8). In the presence of H. pylori infection
in the stomach, H. pylori harbors in GM areas, which
causes duodenitis (9), leading to duodenal ulcer
(8).
Concerning changes in GM after H. pylori eradi-
cation for duodenal ulcer, Noach et al. (10) and
Harris et al. (11) reported no significant differences
between the prevalence and extent of GM before
eradication and those after eradication. Conversely,
Khulusi et al. (12) observed a 42% reduction in the
extent of GM after eradication. Therefore, no con-
sistent findings have been obtained. We previously
reported that GM presented a well-developed appear-
ance with abundant intracellular mucus after suc-
cessful eradication and remained in this condition
for a long period (4).
Previous studies on GM have evaluated the preva-
lence and extent of GM (8) but rarely the proper-
ties of GM. Since there are only a few H. pylori -negative
patients with duodenal ulcer, we previously evalu-
ated differences in the properties of GM (5) between
the presence and absence of H. pylori infection in
patients with endoscopic duodenitis (13). GM showed
the complete type in H. pylori -negative patients with
endoscopic duodenitis but the incomplete type in
H. pylori-positive patients. These findings suggest-
ed the importance of the consideration of not only
the prevalence and extent of GM but also its type
(complete or incomplete) that represents the ma-
turity of H. pylori (5).
In this study, most patients with duodenal ulcer
showed the incomplete type before eradication but
a change to the complete type after eradication and
the persistence of the complete type for a long pe-
riod. However, the patients with recurrence of H. pylori
showed a change to the incomplete type again dur-
ing the follow-up period. In the non-eradication group,
GM changed to the complete type with healing of
the ulcer in some patients but remained the incom-
plete or intermediate type in others. In addition,
most patients with a change to the complete type
after treatment showed a change to the incomplete
type again and a decrease in the GM extent grade
during the follow-up period. These findings were
in contrast to the persistence of the complete type
in the eradication group.
There have been a few studies on the long-term
course of GM after H. pylori eradication, and the
results of these studies have been inconsistent (4,
10-12, 14). In this study, long-term follow up (maxi-
mum, 7.1 years) of GM revealed the persistence of
grade 3 GM extent in most patients until about 2
years after eradication but a subsequent decrease
Fig. 4. Changes in gastric metaplasia in
patients without recurrences (non-eradication
group).
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in the grade in some patients. Kim et al. (14) re-
ported that the prevalence and extent of GM did
not change until 1 year after H. pylori eradication but
decreased slightly 4 years after eradication.
Studies have shown a decrease in acid output after
H. pylori eradication in patients with duodenal ulcer,
but the observation period in these studies was
relatively short (6-12 months after eradication)
(15-18). The development of GM is considered to
be closely associated with gastric high acidity (1,
19, 20). However, the decrease in acid secretion after
eradication may not be adequate to reduce the ex-
tent of GM during only the 2-year period after eradi-
cation. The results of this study and the study by
Kim et al. (14) suggest that a decrease in acid out-
put enough to reduce the extent of GM occurred
2-4 years after eradication in some patients. How-
ever, some patients showed the persistence of grade
3 GM for a long period such as 7.1 years. In these
patients, acid output that induces GM may have been
still sustained. However, even in patients with per-
sistent high acidity, since the complete type of GM
containing abundant mucus persists in the environ-
ment after H. pylori eradication, the defense against
acid may be adequate, and ulcer may not recur (4).
The importance of GM in duodenal ulcer may
be as follows (Fig. 5). GM develops in the healing
process of duodenal erosion and ulcer (3, 19) as a
defense mechanism against high acidity (1, 6-8). In
an H. pylori-positive environment, GM shows the
incomplete type due to invasion and damage by
H. pylori . Since the defense against high acidity may
be decreased in mucosal areas with incomplete type
GM poor in mucus and marked H. pylori -induced
inflammation, ulcer may develop in these areas.
In the healing stage of ulcer, an increase in the extent
of GM and complete type GM are observed in some
patients. However, in a consistently H. pylori -positive
environment, GM decreases in its extent and changes
to the incomplete type again due to H. pylori inva-
sion, and ulcer recurrence is repeated during the
persistence of high acidity (4).
In patients who are H. pylori -negative or after eradi-
cation, complete type GM rich in mucus is observed,
and mucosal inflammation is also mild. Therefore,
the defense against high acidity is adequate, and
ulcer may not develop or recur.
REFERENCES
1. James AH : Gastric epithelium in the duodenum.
Gut 5 : 285-294, 1964
2. Warren JR, Marshall BJ : Unidentified curved
bacilli on gastric epithelium in active chronic
gastritis. Lancet 1 : 1273-1275, 1983
3. Urakami Y : Gastric metaplasia of surface epithe-
lium in the duodenal mucosa. Nippon Shokakibyo
Gakkai Zasshi 72 : 221-231, 1975 (in Japanese
with an English abstract)
4. Urakami Y, Kimura M, Seki H : Gastric metaplasia
and Helicobacter pylori. Am J Gastroenterol
92 : 795-799, 1997
5. Urakami Y, Sano T : Endoscopic duodenitis,
gastric metaplasia and Helicobacter pylori. J
Gastroenterol Hepatol 16 : 513-518, 2001
6. Rhodes J : Experimental production of gastric
epithelium in the duodenum. Gut 5 : 454-458,
1964
7. Tatsuta M, Ishii H, Yamamura H, Yamamoto
R, Taniguchi H : Enhancement by tetragastrin
of experimental induction of gastric epithelium
in the duodenum. Gut 30 : 311-315, 1989
8. Wyatt JI, Rathbone BJ, Sobala GM, Shallcross
T, Heatley RV, Axon ATR, Dixon MF : Gastric
Fig. 5. Relationship between the appearance of gastric metaplasia
and Helicobacter pylori.
The Journal of Medical Investigation Vol. 50 2003 ５３
epithelium in the duodenum : Its association
with Helicobacter pylori and inflammation. J Clin
Pathol 43 : 981-986, 1990
9. Wyatt JI, Rathbone BJ, Dixon MF, Heatley RV :
Campylobacter pyloridis and acid-induced gastric
metaplasia in the pathogenesis of duodenitis.
J Clin Pathol 40 : 841-848, 1987
10. Noach LA, Rolf TM, Bosma NB, Schwartz MP,
Oosting J, Rauws EAJ, Tytgat GNJ : Gastric
metaplasia and Helicobacter pylori infection.
Gut 34 : 1510-1514, 1993
11. Harris AW, Gummett PA, Walker MM, Misiewicz
JJ, Baron JH : Relation between gastric acid out-
put, Helicobacter pylori , and gastric metaplasia
in the duodenal bulb. Gut 39 : 513-520, 1996
12. Khulusi S, Badve S, Patel P, Lloyd R, Marrero
JM, Finlayson C, Mendall MA, Northfield TC :
Pathogenesis of gastric metaplasia of the hu-
man duodenum : Role of Helicobacter pylori,
gastric acid, and ulceration. Gastroenterology
110 : 452-458, 1996
13. Tytgat GNT : The Sydney system : Endoscop-
ic division. Endoscopic appearances in gastri-
tis/duodenitis. J Gastroenterol Hepatol 6 : 223-
234, 1991
14. Kim N, Lim SH, Lee KH, Choi SE : Long-term
effect of Helicobacter pylori eradication on gas-
tric metaplasia in patients with duodenal ulcer.
J Clin Gastroenterol 27 : 246-252, 1998
15. Parente F. Maconi G, Sangaletti M, Minguzzi
M, Vago L, Porro GB : Behaviour of acid secre-
tion, gastrin release, serum pepsinogen, and
gastric emptying of liquids over six months
from eradication of Helicobacter pylori on duo-
denal ulcer patients. A controlled study. Gut
37 : 210-215, 1995
16. El-Omar EM, Penman ID, Ardill JES, Chittajallu
RS, Howie C, McColl KEL : Helicobacter pylori
infection and abnormalities of acid secretion
in patients with duodenal ulcer disease. Gas-
troenterology 109 : 681-691, 1995
17. Harris AW, Gummett PA, Misiewicz JJ, Baron JH :
Eradication of Helicobacter pylori in patients with
duodenal ulcer lowers basal and peak acid out-
puts to gastrin releasing peptide and pentagastrin.
Gut 38 : 663-667, 1996
18. Iijima K, Ohara S, Sekine H, Koike T, Kato K,
Asaki S, Shimosegawa T, Toyota T : Changes
in gastric acid secretion assayed by endoscop-
ic gastrin test before and after Helicobacter pylori
eradication. Gut 46 : 20-26, 2000
19. Patrick WJA, Denham D, Forrest APM : Mu-
cous change in human duodenum ; A light and
electron microscopic study and correlation with
disease and gastric acid secretion. Gut 15 :
767-776, 1974
20. Kreuning J, vd Wal AM, Kuiper G, Lindeman
J : Chronic nonspecific duodenitis. A multiple
biopsy study of the duodenal bulb in health
and disease. Scand J Gastroenterol 24 (Suppl.
167) : 16-20, 1989
Y. Urakami et al. Gastric metaplasia in duodenal ulcer５４
